
T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge, focused on developing TCR-based therapeutics for cancer and autoimmune diseases. Utilizing…

T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge, focused on developing TCR-based therapeutics for cancer and autoimmune diseases. Utilizing…
Headquarters: Granta Park, Cambridge, United Kingdom
Focus: TCR-based therapeutics for oncology and autoimmune disease
Platform: Proprietary OpTiMus® transgenic discovery platform
Founded: 2022
Recent financing: Series A; additional equity injection announced Nov 13, 2025
Improving targeted T cell engagement for treatment of cancer and autoimmune diseases
2022
Biotechnology
$59,000,000
Series A announced in Nov 2023 with a syndicate including Sofinnova Partners, Cambridge Innovation Capital, Cambridge Enterprise, F-Prime, Sanofi Ventures and Digitalis Ventures.
$32,000,000
Additional equity injection announced Nov 13, 2025 adding Tencent and Business Growth Fund to the investor base.
“Company backed by a syndicate including Sofinnova Partners, Cambridge Innovation Capital, Cambridge Enterprise, Digitalis Ventures, F-Prime, Sanofi Ventures, Tencent, Business Growth Fund and University of Cambridge Enterprise”
| Company |
|---|
Job Title: Research Associate/Senior Research Associate
Department: Protein Sciences
Reports To: Head of Protein Sciences
Contract Type: Full time
About the Company
T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge. The company was created to harness the power of T cell biology, to create safe and effective treatments for cancer and autoimmune disease. T-Therapeutics’ experienced team combines world-leading expertise in mouse genome engineering, single cell genomics, biopharmaceutical drug development, machine-learning and structural biology, anchored in a culture of creativity and collaboration.
T-Therapeutics is developing ‘optimal’ TCR bispecific therapeutics using its proprietary OpTiMus® discovery platform, that provides an almost unlimited source of unique, antigen-specific human TCRs. The company is developing a pipeline of first-in-class drugs that are intended to become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases.
Summary:
We are seeking a highly motivated and skilled Research Associate/Senior Research Associate to join our Protein Sciences team. The ideal candidate will have a background in protein purification, biophysical characterisation, and analysis. Experience working with novel format biologics and/or with analytical equipment such as a HPLC would be desirable. The successful candidate will contribute to the purification, and characterization of recombinant proteins to support our drug discovery and development programmes. This role offers an excellent opportunity to work within a fast-paced, cutting-edge research environment and contribute to the advancement of novel therapeutics.
Key Responsibilities:
Qualifications:
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
81,000+
Open Roles
4,600+
New This Week